<?xml version='1.0' encoding='utf-8'?>
<mods xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" version="3.7" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd">
   <name>
      <role>
         <roleTerm type="text" authority="marcrelator" authorityURI="http://id.loc.gov/vocabulary/relators" valueURI="http://id.loc.gov/vocabulary/relators/cre">creator</roleTerm>
      </role>
      <namePart>Zhang, Shuyuan</namePart>
   </name>
   <titleInfo>
      <title>Novel Chelating Agents for Positron Emission Tomography Imaging and Theranostic Applications</title>
   </titleInfo>
   <originInfo>
      <dateCreated keyDate="yes">2022</dateCreated>
   </originInfo>
   <note displayLabel="Degree Awarded">Spring 2022</note>
   <typeOfResource authority="aat" valueURI="http://vocab.getty.edu/page/aat/300028029">Dissertation</typeOfResource>
   <name type="corporate">
      <affiliation>Illinois Institute of Technology</affiliation>
   </name>
   <name type="corporate">
      <namePart>CHEM / Chemistry</namePart>
   </name>
   <name authority="wikidata" authorityURI="https://www.wikidata.org" valueURI="https://www.wikidata.org/wiki/Q92884747">
      <role>
         <roleTerm type="text" authority="marcrelator" authorityURI="http://id.loc.gov/vocabulary/relators" valueURI="http://id.loc.gov/vocabulary/relators/cre">advisor</roleTerm>
      </role>
      <namePart>Chong, Hyun-Soon</namePart>
   </name>
   <subject>
      <topic>Chemistry</topic>
   </subject>
   <subject>
      <topic>Chelator</topic>
   </subject>
   <subject>
      <topic>Histone deacetylase inhibitor</topic>
   </subject>
   <subject>
      <topic>Positron emission tomography</topic>
   </subject>
   <subject>
      <topic>Small molecule ligand-chelator conjugate</topic>
   </subject>
   <subject>
      <topic>Theranostics</topic>
   </subject>
   <subject>
      <topic>Zirconium-89</topic>
   </subject>
   <language>
      <languageTerm type="code" authority="rfc3066">en</languageTerm>
   </language>
   <abstract>Positron emission tomography (PET) is a molecular imaging technology that can be used to detect various diseases including cancer. Zirconium-89 (t1/2 = 78.4 h) is one of the positron-emitting radionuclides that has been widely explored for PET imaging because its half-life matches the long biological half-life of antibody. Research efforts have been devoted to the development of chelation chemistry for 89Zr, a bone-seeking radionuclide. Deferoxamine (DFO) is the most frequently used chelator for 89Zr in both clinical and preclinical trials. DFO can rapidly sequester 89Zr to form 89Zr-DFO complex. However, DFO is not an ideal ligand for 89Zr because 89Zr-labeled DFO-antibody conjugate showed high bone uptake in mice. We wanted to develop novel small molecule donors and novel chelators for 89Zr. We discovered N-methyl-N-(pyridin-2-yl)hydroxylamine (Py-HA) and 2,6-bis(N-methylhydroxylamino)pyridine (Py-BHA) as small molecule donors for 89Zr. Based on the new small molecule donors (Py-HA and Py-BHA), we have designed and synthesized a series of novel macrocyclic chelators containing TACN (1,4,7-triazacyclononane), CYCLEN (1,4,7,10-tetraazacyclododecane), and a diaza-crown ether backbone for 89Zr-based PET imaging applications. Moreover, bifunctional chelators (BFCs) structured on TACN and diaza-18-crown-6 were synthesized for conjugation to antibody. Theranostics contains a diagnostic agent and a therapeutic drug that can be used for simultaneous therapy and imaging of diseases. Radiotheranostics includes radiometal complexes for both therapy and imaging. 177Lu is a promising radiotheranostic metal because it can emit gamma radiation for single photon emission computed tomography (SPECT) imaging and emit β radiation for radiotherapy. A radioisotope pair with complementary emission such as 64Cu/67Cu and 86Y/90Y, can be used for PET imaging and radiotherapy. In this study, we synthesized nonfunctional TACN and diaza crown ether-backboned chelators containing different donor groups for 177Lu, 64Cu/67Cu, and 86Y/90Y. Finally, two bifunctional chelators were synthesized for coupling with hydroxamic acid-based small molecule as a potential histone deacetylase (HDAC) inhibitor to generate a small molecule ligand-chelator conjugate (SMLC) for theranostic applications.
</abstract>
   <physicalDescription>
      <digitalOrigin>born digital</digitalOrigin>
      <internetMediaType>application/pdf</internetMediaType>
   </physicalDescription>
   <accessCondition type="useAndReproduction" displayLabel="rightsstatements.org">In
                Copyright</accessCondition>
   <accessCondition type="useAndReproduction" displayLabel="rightsstatements.orgURI">http://rightsstatements.org/page/InC/1.0/</accessCondition>
   <accessCondition type="restrictionOnAccess">Restricted Access</accessCondition>
<identifier type="hdl">http://hdl.handle.net/10560/islandora:1012253</identifier></mods>